Quick Answer
NUTRA PHARMA CORP reported Revenue (ASC 606) of $246.3 thousand for fiscal year 2024.
NUTRA PHARMA CORP Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $246.3K | +19.8% |
| 2023 | $205.6K | +41.0% |
| 2022 | $145.8K | +49.2% |
| 2021 | $97.7K | +88.3% |
| 2020 | $51.9K | -50.3% |
| 2019 | $104.4K | -20.1% |
| 2018 | $130.6K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $84.5K | +63.5% | +12.7% |
| September 30, 2024 | $75.0K | +45.3% | +45.0% |
| June 30, 2024 | $51.7K | -1.3% | +37.0% |
| March 31, 2024 | $37.7K | -30.8% | -26.9% |
| September 30, 2023 | $51.6K | +109.6% | -1.5% |
| June 30, 2023 | $52.4K | +84.3% | -3.9% |
| March 31, 2023 | $54.5K | +296.3% | +121.4% |
| September 30, 2022 | $24.6K | +27.8% | -13.4% |
- NUTRA PHARMA CORP showed an increase of +19.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2024 period, NUTRA PHARMA CORP’s revenue (asc 606) has grown by 88.6% (from $130.6 thousand to $246.3 thousand).
- The most recent figure is from NUTRA PHARMA CORP’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: